Compare QTRX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTRX | ARCT |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.0M | 163.4M |
| IPO Year | 2017 | 2019 |
| Metric | QTRX | ARCT |
|---|---|---|
| Price | $3.03 | $15.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $6.00 | ★ $24.11 |
| AVG Volume (30 Days) | 847.5K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | $37,632,000.00 | ★ $82,031,000.00 |
| Revenue This Year | $25.49 | N/A |
| Revenue Next Year | $10.04 | $12.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 64.52 | N/A |
| 52 Week Low | $2.15 | $5.50 |
| 52 Week High | $8.77 | $24.14 |
| Indicator | QTRX | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 54.47 | 59.91 |
| Support Level | $2.89 | $6.47 |
| Resistance Level | $3.25 | $17.75 |
| Average True Range (ATR) | 0.19 | 1.39 |
| MACD | 0.09 | -0.23 |
| Stochastic Oscillator | 80.49 | 51.03 |
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.